Photocure ASA
OSE:PHO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
48.05
70.9
|
Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Photocure ASA
Cash from Financing Activities
Photocure ASA
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Photocure ASA
OSE:PHO
|
Cash from Financing Activities
-kr47.5m
|
CAGR 3-Years
-91%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
V
|
Vistin Pharma ASA
OSE:VISTN
|
Cash from Financing Activities
-kr12.6m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
N/A
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Cash from Financing Activities
kr2.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Cash from Financing Activities
kr15.5m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's Cash from Financing Activities?
Cash from Financing Activities
-47.5m
NOK
Based on the financial report for Jun 30, 2024, Photocure ASA's Cash from Financing Activities amounts to -47.5m NOK.
What is Photocure ASA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-91%
Over the last year, the Cash from Financing Activities growth was 17%. The average annual Cash from Financing Activities growth rates for Photocure ASA have been -91% over the past three years .